Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Fineline Cube May 24, 2026
Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Fineline Cube May 24, 2026
Company Deals

Shanghai OPM Biosciences Plans Acqusition of PharmaLegacy Labs for RMB 1.45 Billion

Fineline Cube Jun 6, 2025

Shanghai OPM Biosciences Co., Ltd (SHA: 688293), a China-based cell culture-focused Contract Development and Manufacturing...

Company Drug

Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis

Fineline Cube Jun 6, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...

Policy / Regulatory

NHSA Strengthens Pharmaceutical Pricing and Procurement Credit Evaluation Mechanism

Fineline Cube Jun 6, 2025

The National Healthcare Security Administration (NHSA) issued a notification this week to refine its credit...

Policy / Regulatory

China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations

Fineline Cube Jun 6, 2025

China’s National Medical Products Administration (NMPA), Ministry of Finance (MoF), and State Administration for Market...

Policy / Regulatory

China’s National Health Commission Mandates Labor Pain Management Services Expansion

Fineline Cube Jun 6, 2025

China’s National Health Commission (NHC) issued a notification mandating the comprehensive promotion of labor pain...

Company Deals

Intragrand Pharma Licenses Lenamilast to Transpire Bio for Global Development

Fineline Cube Jun 6, 2025

China-based Suzhou Intragrand Pharma has entered into a licensing agreement with U.S.-headquartered Transpire Bio Inc....

Company Deals

Consun Pharma Partners with DP Technology to Accelerate AI-Driven Kidney Disease Drug R&D

Fineline Cube Jun 6, 2025

China-based Consun Pharmaceutical Group Ltd (HKG: 1681) announced a strategic partnership with compatriot firm DP...

Company Drug

Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE

Fineline Cube Jun 5, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion...

Company Drug

BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes

Fineline Cube Jun 5, 2025

US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received an indication extension...

Company Deals

Shanghai Pharma Partners with Chugai Pharma China to Enhance Bone Health Products

Fineline Cube Jun 5, 2025

China’s Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607; SPH) has established a partnership...

Company Deals

Genrix Bio Partners with Cullinan Therapeutics for GR1803 License

Fineline Cube Jun 5, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...

Company Drug

AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China

Fineline Cube Jun 5, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) received approval from China’s National Medical Products Administration...

Company Drug

Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication

Fineline Cube Jun 5, 2025

China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...

Company Drug

Salubris Pharmaceuticals’ Allisartan-Indapamide Hybrid Wins NMPA Approval

Fineline Cube Jun 5, 2025

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, announced that it has...

Company Drug

Wantai Biopharm’s Cecolin 9 HPV Vaccine Approved by China’s NMPA

Fineline Cube Jun 5, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its 9-valent human...

Company Drug

Biocytogen and Chia Tai Tianqing Win NMPA Approval for NTB003 Clinical Trials

Fineline Cube Jun 5, 2025

Chinese partners Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) and Chia Tai Tianqing announced that...

Company Drug

NMPA Accepts NDA for Innovent and HutchMed’s Tyvyt and Elunate Combination

Fineline Cube Jun 5, 2025

Chinese companies Innovent Biologics, Inc. (HKG: 1801) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013)...

Company Deals

SciBrunch Therapeutics Secures RMB 200 Million in Angel Financing Round

Fineline Cube Jun 5, 2025

Shanghai-based SciBrunch Therapeutics, a developer of small molecule anti-tumor drugs, has reportedly secured over RMB...

Company Drug

JW Therapeutics’ Carteyva Approved by Macau Health Bureau

Fineline Cube Jun 5, 2025

JW Therapeutics (HKG: 2126), a clinical-stage cell therapy company co-founded in 2016 by Juno Therapeutics...

Company Deals

Sichuan Kelun-Biotech Raises $250M in Hong Kong’s Largest Follow-On Offering

Fineline Cube Jun 5, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced the successful placement of 5,918,000 new...

Posts pagination

1 … 153 154 155 … 670

Recent updates

  • Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma
  • Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer
  • Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors
  • Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026
  • Qyuns Therapeutics and Huadong Medicine Secure NMPA Approval for Stelara Biosimilar HDM3001-2/QX001S in Crohn’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Junshi Biosciences Secures NMPA Approval for Loqtorzi Combination Therapy in HER2-Expressing Urothelial Carcinoma

Company Drug

Shanghai Henlius Biotech Secures Australian TGA Approval for Phase I Trial of HLX3902 Trispecific T-Cell Engager in Prostate Cancer

Company Drug

Shanghai Henlius Biotech Secures NMPA Approval for Phase I Trial of HLX48 Bispecific ADC in Advanced Solid Tumors

Company Drug

Sino Biopharmaceutical Presents Positive Phase III and II Data for M701 Bispecific Antibody at ASCO 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.